Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. The company was founded in 2001 and is based in Perth, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.53382933576858 | N/A |
Market Cap | $62.17M | N/A |
Shares Outstanding | 116.45M | 10.35% |
Employees | 0 | N/A |
Shareholder Equity | 8.32M | 145.25% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -9.98 | N/A |
P/S Ratio | 126.76 | N/A |
P/B Ratio | 7.47 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.5030 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $490.41K | N/A |
Earnings | -$4.19M | N/A |
EPS | -0.0535 | N/A |
Earnings Yield | -0.1002 | N/A |
Gross Margin | 1.00 | N/A |
Operating Margin | -12.07 | N/A |
Net income margin | -8.54 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $6.77M | N/A |
Total Debt | $43.03K | N/A |
Cash on Hand | $4.05M | N/A |
Debt to Equity | 0.1414 | -64.32% |
Cash to Debt | $94.05 | N/A |
Current Ratio | $7.55 | 194.55% |